MiNK Therapeutics, Inc. reported financial results for the first quarter ending March 31, 2026.
“On May 15, 2026, MiNK Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026.”
MiNK Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from MiNK Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MiNK Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income net loss for the quarter ended December 31, 2025, was $2.6 million, or $0.56 per share.
“On March 31, 2026, MiNK Therapeutics, Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2025.”
MiNK Therapeutics, Inc.: Filed Certificate of Amendment to effect a 1-for-10 reverse stock split of common stock (effective 2025-01-28).
“On January 17, 2025, MiNK Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.00001 (the “Common Stock”) at a ratio of 1-for-10 (the “Reverse Stock Split”).”
Robert Kadlec was elected as Director at MiNK Therapeutics, Inc..
“On October 30, 2024, the Board of Directors (the “Board”) of MiNK Therapeutics Inc., ("MiNK") elected Dr. Robert Kadlec to become a Class II director of MiNK with an initial term that expires at MiNK's annual meeting of stockholders in 2026.”
Dr. Marc Van Dijk changed role as Chief Scientific Officer at MiNK Therapeutics, Inc..
“Dr. Marc Van Dijk will transition from his role as Chief Scientific Officer and assume the positions of Scientific Advisory Board Member and Strategic Consultant.”
MiNK Therapeutics, Inc. reported for the first quarter 2024 results: net income $3.8 million, or $0.11 per share, EPS $0.11 per share.
“Net loss for the first quarter of 2024 was $3.8 million, or $0.11 per share, compared to $5.7 million, or $0.17 per share, for the first quarter of 2023.”
MiNK Therapeutics, Inc. reported fourth quarter and full-year 2023 results: net income Net loss for the year ended December 31, 2023 was $22.5 million, or $0.65 per share, EPS $0.65.
“MiNK Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2023.”
MiNK Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 26, 2024, the Company received a letter (the “Minimum Bid Price Notice”) from Nasdaq notifying the Company that its Class A common stock, $0.0001 par value per share (the “Common Stock”), failed to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) based upon the closing bid price of the Common Stock for the 30 consecutive trading days prior to the date of the Minimum Bid Price Notice from Nasdaq. The Company has been provided an initial compliance period of 180 calendar d”
MiNK Therapeutics, Inc. incurred convertible notes of up to $5.0 million with Agenus Inc. at 2% maturing on or after January 1, 2026.
“On February 12, 2024, MiNK Therapeutics, Inc. (the “Company”) and Agenus Inc. (“Agenus”) entered into a Convertible Promissory Note Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company issued to Agenus a Convertible Promissory Note in the principal amount of up to $5.0 million (the “Note”).”
MiNK Therapeutics, Inc. entered into Convertible Promissory Note Purchase Agreement with Agenus Inc. valued at $5.0 million (effective 2024-02-12).
“On February 12, 2024, MiNK Therapeutics, Inc. (the “Company”) and Agenus Inc. (“Agenus”) entered into a Convertible Promissory Note Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company issued to Agenus a Convertible Promissory Note in the principal amount of up to $5.0 million (the “Note”).”
MiNK Therapeutics, Inc. reported third quarter 2023 results: net income $17 million, or $0.50 per share, EPS ($0.50).
“Net loss for the nine-months ended September 30, 2023 was $17 million, or $0.50 per share, compared to net loss for the same period in 2022 of $20.2 million or $0.60 per share.”
Dr. John Baldoni resigned as director at MiNK Therapeutics, Inc..
“On October 12, 2023, Dr. John Baldoni sent notice of his resignation as a director at MiNK Therapeutics, Inc. (the "Company"), effective October 31, 2023.”
MiNK Therapeutics, Inc. reported the second quarter 2023 results: net income Net loss for the six-months ended June 30, 2023 was $11.9 million, or $0.35 per share.
“On August 10, 2023, MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2023.”
MiNK Therapeutics, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-13 meeting.
“The votes cast at the Annual Meeting were as follows: For Against Withheld Broker Non-Votes 30,644,494 5,764 110,413 NA”
MiNK Therapeutics, Inc. shareholders approved Election of Garo Armen and Barbara Ryan as Class II directors at the 2023-06-13 meeting.
“Class II Director Nominees For Against Withheld Broker Non-Votes Garo Armen 29,157,446 0 282,326 1,320,899 Barbara Ryan 29,193,530 0 246,242 1,320,899”
MiNK Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income $5.7 million or $0.17 per share, EPS $0.17 per share.
“Net loss for the quarter ended March 31, 2023, was $5.7 million or $0.17 per share”
MiNK Therapeutics, Inc. reported the year ended December 31, 2022 results: net income $28.0 million, EPS $0.83 per share.
“Net loss for the year ended December 31, 2022, was $28.0 million, or $0.83 per share compared to $30.2 million and $1.16 per share for the year ended December 31, 2021.”
MiNK Therapeutics, Inc. reported the quarter ended December 31, 2022 results: net income $7.8 million, EPS $0.23 per share.
“Net loss for the quarter ended December 31, 2022, was $7.8 million or $0.23 per share, compared to a net loss for the same period of 2021 of $5.8 million or $0.18 per share.”
MiNK Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $6.3 million or $0.19 per share, EPS $0.19 per share.
“Net loss for the quarter ended September 30, 2022, was $6.3 million or $0.19 per share”
Walter Flamenbaum retired as Director at MiNK Therapeutics, Inc..
“Dr. Walter Flamenbaum retired from the Board of Directors of MiNK Therapeutics, Inc. (the “Company”), effective December 31, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.